A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis by Bruce W. Kirkham, Alexander Egeberg, Frank Behrens, Andreas Pinter, Joseph F. Merola, Thorsten Holzkämper, Gaia Gallo, Khai Jing Ng, Rebecca Bolce, Christopher Schuster, Peter Nash, Luis Puig

Subjects: Get full text

The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel by Joshua Burshtein, Milaan Shah, Danny Zakria, Benjamin Lockshin, Jeff Crowley, Joseph F. Merola, Ken Gordon, Mona Shahriari, Neil J. Korman, Raj Chovatiya, Robert Kalb, Mark Lebwohl

Subjects: “…Psoriasis…”
Get full text

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis by Ana-Maria Orbai, Soumya D. Chakravarty, Yin You, May Shawi, Ya-Wen Yang, Joseph F. Merola

Subjects: Get full text

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence by Jashin J. Wu, Joseph F. Merola, Steven R. Feldman, Alan Menter, Mark Lebwohl

“…Abstract Psoriasis (PsO) is a common, systemic, chronic, inflammatory disease characterized by key clinical symptoms, including itching, pain, and scaling. …”
Get full text

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes by Alexander Egeberg, Joseph F. Merola, Knut Schäkel, Luis Puig, Patrick D. Mahar, Patrick D. Mahar, Isabella Yali Wang, Imre Pavo, Christopher Schuster, Christopher Schuster, Christopher E. M. Griffiths

Subjects: “…moderate-to-severe psoriasis…”
Get full text

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes by Alexander Egeberg, Joseph F. Merola, Knut Schäkel, Luis Puig, Patrick D. Mahar, Patrick D. Mahar, Isabella Yali Wang, Imre Pavo, Christopher Schuster, Christopher Schuster, Christopher E. M. Griffiths

Subjects: “…moderate-to-severe psoriasis…”
Get full text

A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis by Alice B. Gottlieb, Joseph F. Merola

Subjects: “…psoriasis…”
Get full text

Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis by Steven R. Feldman, Joseph F. Merola, David M. Pariser, Jingchuan Zhang, Yang Zhao, Alan M. Mendelsohn, Alice B. Gottlieb

Subjects: “…psoriasis…”
Get full text

Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity by Mwangi J. Murage, Amanda Anderson, Deborah Casso, Susan A. Oliveria, Clement K. Ojeh, Talia M. Muram, Joseph F. Merola, Art Zbrozek, Andre B. Araujo

Subjects: “…psoriasis…”
Get full text

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program by Alice B. Gottlieb, Russel Burge, William N. Malatestinic, Baojin Zhu, Yunyang Zhao, Julie McCormack, Miriam Kimel, Joseph F. Merola

Subjects: Get full text

Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims Database by Joseph F. Merola, Dhaval Patil, Antton Egana, Andrea Steffens, Noah S. Webb, Alice B. Gottlieb

Subjects: Get full text

Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials by Atul Deodhar, Andrew Blauvelt, Mark Lebwohl, Meghan Feely, Andris Kronbergs, Nadezhda Eberhart, Danting Zhu, Elsa Inman, Elsie Grace, Thorsten Holzkaemper, Proton Rahman, Helena Marzo-Ortega, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Sergio Schwartzman

Subjects: Get full text

Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT Survey by Joseph F. Merola, Alexis Ogdie, Alice B. Gottlieb, Linda Stein Gold, Andrea Flower, Shauna Jardon, Yuri Klyachkin, Mark Lebwohl

Subjects: Get full text

Psoriatic arthritis for dermatologists by Alice Gottlieb, Joseph F. Merola

Subjects: Get full text

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Regi... by Philip J. Mease, Alexis Ogdie, John Tesser, Natalie J. Shiff, Iris Lin, Soumya D. Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R. McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F. Merola

“…Hierarchical, multiplicity-controlled primary and secondary outcomes were mean (95% confidence interval) changes from baseline at 6 months in clinical Disease Activity Index for PsA (cDAPSA; primary), Physician Global Assessment (PGA) of arthritis and psoriasis (visual analog scale [VAS] 0–100), patient-reported pain (VAS 0–100), and percent body surface area with psoriasis (%BSA). …”
Get full text

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies by Peter C. Taylor, Andrew G. Bushmakin, Joseph C. Cappelleri, Pamela Young, Rebecca Germino, Joseph F. Merola, Gil Yosipovitch

“…Repeated measures longitudinal models assessed relationships between dermatologic assessments (predictors) Itch Severity Item (ISI), Physician’s Global Assessment of Psoriasis (PGA-PsO), and Patient’s Global Joint and Skin Assessment-Visual Analog Scale-Psoriasis question (PGJS-VAS-PsO), and QoL measures (outcomes) Dermatology Life Quality Index (DLQI) and Short Form-36 Health Survey Version 2 (SF-36v2). …”
Get full text

Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis by Peter C. Taylor, Andrew G. Bushmakin, Joseph C. Cappelleri, Pamela Young, Rebecca Germino, Joseph F. Merola, Gil Yosipovitch

“…Mediation modeling assessed the indirect effects (via Itch Severity Item [ISI] and Physician’s Global Assessment of Psoriasis [PGA-PsO]) and direct effects (via all other factors) of tofacitinib treatment on dermatology-specific HRQoL (measured by Dermatology Life Quality Index [DLQI]). …”
Get full text

Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled... by Joseph F. Merola, April Armstrong, Saakshi Khattri, So Yeon Paek, Byron Padilla, Cuiyong Yue, Huzefa Photowala, Blair Kaplan, Lars Erik Kristensen

“…This post hoc integrated analysis evaluated achieving the following efficacy outcomes at weeks 24 and 52 by baseline demographics and clinical characteristics: ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70), ≥90% improvement in Psoriasis Area and Severity Index, minimal disease activity status, Low Disease Activity status (Disease Activity in Psoriatic Arthritis), and minimal clinically important difference in pain. …”
Get full text

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study by Iain B. McInnes, Koji Kato, Marina Magrey, Joseph F. Merola, Mitsumasa Kishimoto, Derek Haaland, Liang Chen, Yuanyuan Duan, Jianzhong Liu, Ralph Lippe, Peter Wung

“…Proportions of patients achieving ≥ 20%/50%/70% improvement in American College of Rheumatology criteria (ACR20/50/70), ≥ 75%/90%/100% improvement in Psoriasis Area and Severity Index (PASI75/90/100), or minimal disease activity (MDA) were maintained through week 104; greater responses by nominal P value were observed with UPA15 and UPA30 versus ADA for ACR20/50/70 and MDA. …”
Get full text